Drug therapy of depression with anhedonia - to findings of the questionnaire survey of 1020 Russian psychiatrists
Clinical review for general practice · 16.11.2026 · 7 (9) · 112-118
DOI: 10.47407/kr2026.7.9.00938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 16.11.2026. Verfasst von Olga A Karpenko und 4 weiteren Autor:innen.
Themen: Depression
Abstract (Originalsprache)
Background
Results of a previously conducted survey of practicing Russian psychiatrists revealed substantial variability in opinions regarding the pharmacotherapy of anhedonia. This article presents the results of a detailed, previously unpublished analysis of these opinions, reflecting practicing specialists’ current understanding of the pharmacotherapeutic options for anhedonia.
Methods
Data from an online survey of 1020 practicing psychiatrists, collected between March and September 2025, were used. Open-ended responses to the questionnaire were thematically categorized, followed by statistical analysis of associations between the choice of psychopharmacotherapy and various sociodemographic and professional factors. Logistic regression was also performed to jointly assess the effects of sociodemographic and professional characteristics on the likelihood of mentioning venlafaxine as an effective medication for the treatment of anhedonia.
Results
Although SSRIs were the most frequently mentioned antidepressant class considered effective for anhedonia by respondents (21,9% physicians), the most frequently mentioned individual antidepressants were venlafaxine (17,1% physicians), vortioxetine (13,7% physicians), agomelatine (12,5% physicians), and sertraline (8,6% physicians). Several characteristics were found to significantly increase the likelihood of mentioning venlafaxine: identifying melancholic depression (OR 2.609) as the type of depression most commonly associated with anhedonia, and working at a research center (OR 1.964). Working in a public healthcare institution significantly reduced the likelihood of selecting venlafaxine (OR 0.377).
Discussion
The findings demonstrated that the overall pattern of opinions among practicing Russian psychiatrists regarding the pharmacotherapy of anhedonia is consistent with the established international evidence base. At the same time, these data may provide a basis for personalized educational programs for psychiatrists, as well as for targeted invitations to training programs that take the identified characteristics into account. Keywords: anhedonia, pharmacotherapy, antidepressants, venlafaxine.
Zitieren
APA
Karpenko, O. A., Kibitov, A. A., Medvedev, V. E., Medvedev, V. E., & Mukhin, A. A. (2026). Drug therapy of depression with anhedonia - to findings of the questionnaire survey of 1020 Russian psychiatrists. Clinical review for general practice, 7(9), 112-118. https://doi.org/10.47407/kr2026.7.9.00938
Vancouver
Karpenko OA, Kibitov AA, Medvedev VE, Medvedev VE, Mukhin AA. Drug therapy of depression with anhedonia - to findings of the questionnaire survey of 1020 Russian psychiatrists. Clinical review for general practice. 2026;7(9):112-118. doi:10.47407/kr2026.7.9.00938
BibTeX
@article{Karpenko2026,
author = {Karpenko, Olga A and Kibitov, Andrey A and Medvedev, Vladimir E and Medvedev, Vladimir E and Mukhin, Alexander A},
title = {Drug therapy of depression with anhedonia - to findings of the questionnaire survey of 1020 Russian psychiatrists},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {9},
pages = {112--118},
doi = {10.47407/kr2026.7.9.00938}
}
EUVIMED